Stockhub

Lytix Biopharma AS: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 August 2022

  • curprev 08:2508:25, 22 August 2022 >Nick 778 bytes +778 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such..."
Retrieved from "https://stockhub.co/research/Lytix_Biopharma_AS"